Corey J. Langer, MD

Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.

Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.

Corey J. Langer, MD, discusses findings from the ongoing phase 2 PHAROS trial in patients with non–small cell lung cancer harboring BRAF V600E mutations.

Corey J. Langer, MD, discusses the benefit observed with the continued treatment of atezolizumab following disease progression in patients with advanced non–small cell lung cancer.

Corey J. Langer, MD, professor of medicine, University of Pennsylvania, director, Thoracic Oncology, Penn Medicine, discusses the evolution of molecular testing in advanced non–small cell lung cancer.

Corey J. Langer, MD, discusses the need for reflex testing in patients with non–small cell lung cancer.

Corey J. Langer, MD, director, thoracic oncology, Penn Medicine, discusses the future of immunotherapy during a discussion about KEYNOTE-021 at the 2019 World Conference on Lung Cancer.

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the current state of immunotherapy in advanced non–small cell lung cancer.

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of durvalumab in stage III non–small cell lung cancer.

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the use of next-generation sequencing in non–small cell lung cancer.

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of targeted therapy in non–small cell lung cancer.

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of the PACIFIC trial results on the treatment landscape of stage III non–small cell lung cancer.

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of frontline immunotherapy in lung cancer.

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the practice-changing data from the PACIFIC trial, which evaluated durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy.

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of the IMpower150 trial in patients with non–small cell lung cancer (NSCLC).

Corey Langer, MD, the director of Thoracic Oncology at the University of Pennsylvania, discuses afatinib, which was approved in 2013 for first line EGFR-mutated advanced non-small cell lung cancer.

Corey J. Langer, MD, professor of medicine, hematology/oncology division, University of Pennsylvania, Abramson Cancer Center, discusses the treatment of patients with early stage lung cancer.

Corey J. Langer, MD, from the University of Pennsylvania, Abramson Cancer Center, discusses integrating the irreversible pan-HER inhibitor afatinib into the treatment paradigm for patients with advanced non-small cell lung cancer.

Corey J. Langer, MD, from the University of Pennsylvania, Abramson Cancer Center, discusses the EGFR-targeted tyrosine kinase inhibitor erlotinib for patients with non-small cell lung cancer.

Corey J. Langer, MD, from the Abramson Cancer Center, discusses the investigation of targeted therapies for patients with locally advanced non-small cell lung cancer.

Dr. Corey Langer, from the University of Pennsylvania, Abramson Cancer Center, Discusses Treating Locally Advanced Non-small Cell Lung Cancer.

Dr. Corey Langer from the Abramson Cancer Center Discusses the PARAMOUNT Study

Dr. Corey Langer from Abramson Cancer Center on Cost Analysis in the Treatment Decision

Dr. Corey J. Langer from Abramson Cancer Center Discusses the JMEN Maintenance Pemetrexed Trial

Dr. Corey J. Langer from Abramson Cancer Center on Assessing Patient Populations in Clinical Trials